Dr. Jonathan Rosenberg, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 764
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: New York University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NY license 210363
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- NYU Langone Hospitals New York, NY
Medical groups
- New York University (6,134 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 764
- Services billed
- 1,707
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 535 | 374 |
| Biopsy of large bowel using a flexible endoscope | 239 | 239 |
| Established patient office or other outpatient visit, 30-39 minutes | 161 | 138 |
| Insertion of needle into vein for collection of blood sample | 143 | 116 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 119 | 114 |
| New patient office or other outpatient visit, 30-44 minutes | 112 | 112 |
| New patient office or other outpatient visit, 45-59 minutes | 85 | 85 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 77 | 77 |
| Imaging of digestive tract done from the inside of the digestive tract | 56 | 55 |
| Injection beneath lining of large bowel using a flexible endoscope | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Famotidine Other prescribers in New York, NY | 401 |
| Omeprazole Other prescribers in New York, NY | 313 |
| Pantoprazole Sodium Other prescribers in New York, NY | 271 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in New York, NY | 187 |
| Dexlansoprazole Dr (dexlansoprazole) Other prescribers in New York, NY | 93 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in New York, NY | 70 |
| Lansoprazole Other prescribers in New York, NY | 59 |
| Linzess (linaclotide) Other prescribers in New York, NY | 53 |
| Rabeprazole Sodium Other prescribers in New York, NY | 46 |
| Mesalamine Other prescribers in New York, NY | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $49,556 in research payments for these studies, mostly to the institutions running them.
- A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative…
Teva Pharmaceuticals USA, Inc. - A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE …
Teva Pharmaceuticals USA, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.